Clinical trials: Paracetamol Toxicity
Acute Liver Failure, Hepatic Encephalopathy
N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
We have completed patient enrollment in the the double blind, randomized, placebo-controlled trial of intravenous (IV) N-acetylcysteine (NAC) vs. placebo for the treatment of non-acetaminophen ALF.
- Trial name
- NCT00248625
- Testing
- N-acetylcysteine
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 184 people
- Sponsor
- University of Pittsburgh
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Drug Toxicity, Healthy
Aminotransferase Trends During Prolonged Acetaminophen Dosing
The objective of this study is to monitor liver function tests (blood levels of an indicator of liver function) of healthy people taking the maximum labeled daily dose of acetaminophen compared to people taking placebo for 16 to…
- Trial name
- NCT00743093
- Testing
- acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 398 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Acetaminophen Metabolism, Acetaminophen Poisoning
Effect on Acetaminophen Metabolism by Liquid Formulations
The purpose of this study is to determine whether excipients in the liquid formulation of acetaminophen prevent the formation of the toxic metabolites of acetaminophen.
- Conditions
- Acetaminophen Metabolism, Acetaminophen Poisoning, Drug Metabolism by Excipients
- Trial name
- NCT01246713
- Testing
- Acetaminophen liquid formulation, Acetaminophen solid formulation
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Liver Failure
13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
The ALFSG-MBT protocol is for a multicenter, open label, non-randomized study to determine the value of Breath Identification® (BreathID®) N-(4-Methoxy-13C-phenyl)acetamide (13C-Methacetin) Breath Test System in predicting the…
- Trial name
- ALFSG-MBT (NCT02786836)
- Testing
- 13C-Methacetin
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- University of Texas Southwestern Medical Center
Acetaminophen Toxicity
Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
A purpose of this protocol is to is to compare the metabolites of the toxic bioactivating pathway after acetaminophen alone or acetaminophen followed by Propylene Glycol (PG) and to determine if it prevents the formation of the…
- Trial name
- APAPII (NCT02322879)
- Testing
- First Treatment Period, Washout, Second Treatment Period
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center